Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Englund

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Psychological Medicine|May 4, 2026
Changes in cannabis potency and cannabis-related psychiatric harms: a 23-year ecological study in DenmarkKristine Rømer Thomsen, Birgitte Thylstrup, Morten Hesse, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Journal of Psychopharmacology (Oxford, England)|October 9, 2012
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentAmir Englund, Paul D Morrison, Judith Nottage, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Neuroscience and Biobehavioral Reviews|May 6, 2024
Exploring causal mechanisms of psychosis riskDominic Oliver, Edward Chesney, Alexis E Cullen, et al.
Addiction (Abingdon, England)|February 7, 2023
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experimentWill Lawn, Katie Trinci, Claire Mokrysz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
Addiction (Abingdon, England)|September 30, 2021
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis useValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Psychological Medicine|May 4, 2026
Changes in cannabis potency and cannabis-related psychiatric harms: a 23-year ecological study in DenmarkKristine Rømer Thomsen, Birgitte Thylstrup, Morten Hesse, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Journal of Psychopharmacology (Oxford, England)|October 9, 2012
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentAmir Englund, Paul D Morrison, Judith Nottage, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Neuroscience and Biobehavioral Reviews|May 6, 2024
Exploring causal mechanisms of psychosis riskDominic Oliver, Edward Chesney, Alexis E Cullen, et al.
Addiction (Abingdon, England)|February 7, 2023
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experimentWill Lawn, Katie Trinci, Claire Mokrysz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
Addiction (Abingdon, England)|September 30, 2021
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis useValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Pageof 4